Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
about
Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in ItalyDeep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness AnalysisCost effectiveness of preventing falls and improving mobility in people with Parkinson disease: protocol for an economic evaluation alongside a clinical trialQuantifying the profile and progression of impairments, activity, participation, and quality of life in people with Parkinson disease: protocol for a prospective cohort study.Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected.An exercise intervention to prevent falls in Parkinson's: an economic evaluationA quantitative dynamic systems model of health-related quality of life among older adults.Clinical predictors of frequent patient telephone calls in Parkinson's disease.Geographic model and biomarker-derived measures of pesticide exposure and Parkinson's disease.Inpatient management of Parkinson disease: current challenges and future directionsThe cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's diseaseModelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease.Economic Burden Analysis of Parkinson's Disease Patients in ChinaAlzheimer's and Parkinson's Diseases: Expected Economic Impact on Europe-A Call for a Uniform European Strategy.Effect of cognitive behavior therapy on sleep disorder in Parkinson's disease in China: a pilot study.Cost-of-illness in multiple system atrophy and progressive supranuclear palsy.Drug and treatment costs in Parkinson's disease patients in Sweden.Average annual cost of Parkinson's disease in São Paulo, Brazil, with a focus on disease-related motor symptoms.Do nonmotor symptoms in Parkinson's disease differ from normal aging?Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease.Economic burden of Parkinson's disease in Singapore.Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany.Early retirement and income loss in patients with early and advanced Parkinson's disease.Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.Parkinson's disease and sleep/wake disturbances
P2860
Q24793543-CE7DE685-407A-4F35-8C72-E3B394A6AB52Q26779605-5937D4A2-A6A4-46BA-968D-8F9A56359CDDQ33372608-82C4A99B-914B-429B-889D-1A3CAA18BA3AQ33400886-60485032-C47B-4B9B-9C9B-C2056D7A9C96Q34239492-0C9C0082-6C0F-4404-A608-F36CB0C06EB7Q34487026-DA289187-AA11-4999-8A73-50DDD5A63379Q36244201-D27F4567-E570-4FBF-95B2-F577D07E7979Q36728875-A82F21A8-A068-4724-9BDA-BA01A6F27CA6Q36851276-D19D0EE7-DFA6-42B8-A0A5-273E54E8F719Q37052711-CCB023AA-EA42-4AE2-AF0B-1611BBEC0BE6Q37491322-692705B2-5B4F-4219-A2F8-8C0253D2F4E0Q37955238-5214A0E3-08C1-4C31-9ED3-B2A87DF2696EQ38122127-1D725F94-ABFC-4B05-987E-6C923F9F19B5Q38659681-92FDB7FA-BF84-4681-8876-C13D3FFE0CA1Q39446997-AC1E3FA4-1A70-476D-BAAE-7BA382537263Q39513377-1BE2B7CC-B507-44EB-9FBC-529730C2612EQ39762141-0456E5EB-C86A-4618-B105-6894C7D60C33Q39763335-64BD8B7E-74BC-4F8D-9F61-19EC3C407FA5Q47098412-85FF394C-3018-47F7-A158-2D76755E3A65Q48298494-56366079-9ADB-425A-9649-4338323E3139Q48583756-E5C823EF-F22F-4412-9B48-57BDD37DC662Q48793129-3D9B4E3B-576F-4269-B2EC-63D7391640E5Q51143314-DEB93755-9FC7-45CD-89F0-516C6638A2E6Q53145923-5EF4BD89-4FEC-482E-8784-ACD13D9ABDDFQ53930312-ABA98432-2B33-4C9D-938A-1F7C34A9096DQ58913404-FD9C4890-9A62-42A8-8BBE-8FCACDDB6E80
P2860
Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
@ast
Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
@en
type
label
Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
@ast
Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
@en
prefLabel
Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
@ast
Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
@en
P2093
P356
P1433
P1476
Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
@en
P2093
Jan Reimer
Martin Grabowski
Peter Hagell
Sara Nordling
Ulf Persson
P304
P356
10.1002/MDS.10262
P407
P577
2002-11-01T00:00:00Z